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Background. Essential thrombocythemia (ET) and primary myelofibrosis (MF) are 
myeloproliferative neoplasms characterized by the overproduction of mature cells such as platelets 
(ET) or early bone marrow fibrosis due to scarring induced by highly proliferating myeloid 
progenitors and pathological stimulation of local fibroblasts (MF). Somatic mutations in CALR 
gene have recently identified in the majority of JAK2-V617F and MPL negative ET and MF 
patients. In this study we evaluated the frequency and type of CALR mutations and their clinical 
and hematological features. 
 
Methods. A total of 54 patients, 29 ET and 25 MF patient, was included in this study. All patients 
were JAK2 V617F and MPL negative. We registered clinical and hematological characteristics of 
patients i.e. age, hemoglobin level, white blood cell count, platelet count, International Prognostic 
Scoring System (IPSS),  risk of thrombosis. Samples were collected from peripheral blood and 
DNA was extracted by using the QIAamp DNA mini kit (QIAGEN); CALR mutations were 
analyzed by direct sequencing method. 
 
Results. CALR mutations were present in 20.4 % of patients (4 ET; 7 MF). Four types of CALR 
mutations were detected; type 1 (p.L367fs*46) was isolated in 6 MF patient,  type 2 (p.K385fs*47) 
was isolated in 3 ET patient; we also found 2 deletion mutations (p.E371fs*49 and D373fs*47), 
which are less common deletions, in the remaining patients. Patients carrying CALR mutations 
were younger (mediane age: 50 vs 65; p=0.2) than CALR negative patients. Furthermore, they did 
not show thrombosis and IPSS high risk. 
 
Conclusions. Our observations are in agreement with the findings of literature. We can assert an 
improved outcome of CALR mutated patients and we can also speculate a possible protective role 
of CARL mutations given the absence of thrombosis events and of IPSS high risk. However, the 
cohort of patients with myeloproliferative disease need to be implemented to draw final conclusion.   
 
 
 
